Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium alginate is the sodium salt of alginic acid—a hydrophilic polysaccharide extracted from brown seaweed. It is widely used as a stabilizer, thickener, and emulsifier in food products and as an excipient in pharmaceuticals[2][3]. In medicine—particularly for gastroesophageal reflux disease (GERD) and heartburn—sodium alginate acts by forming a viscous gel or "raft" upon contact with gastric acid. This raft floats on top of stomach contents to create a physical barrier that prevents reflux of gastric acids into the esophagus[1][4][5]. Sodium alginate is also found in antacid formulations such as Gaviscon. Its mechanism does not involve systemic absorption but rather mechanical protection via gel formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sodium alginate.